Bounded definition
The cited mammalian-cell experiments report locus-specific indels and templated edits after CRISPR-Cas9 cleavage under defined conditions. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Multiplex Genome Engineering Using CRISPR/Cas Systems.
Definition and evidence boundary
Cellular repair of a targeted DNA break through end joining, templated repair, and other context-dependent pathways. The bounded proposition retained by the canonical record is: The cited mammalian-cell experiments report locus-specific indels and templated edits after CRISPR-Cas9 cleavage under defined conditions.
The applicable scope is The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Multiplex Genome Engineering Using CRISPR/Cas Systems. This definition must not be generalized beyond the cited source and exact record boundary.
Claims: urn:maha:claim:double-strand-break-repair-outcomes
Mechanism and technical context
The study demonstrates CRISPR-Cas9 genome targeting and multiplex editing in mammalian cells under specified constructs, loci, delivery, and assays. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.
Repair distributions vary with cell state, locus, template, timing, delivery, assay, and selection and cannot be reduced to one universal outcome. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.
Claims: urn:maha:claim:double-strand-break-repair-outcomes
How to interpret the evidence
There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices. The evidence maturity recorded here is single study, and the claim kind is empirical claim.
This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded. Cell-culture demonstrations do not establish organism-level delivery, clinical safety, durable benefit, or universal target performance. These qualifications travel with the claim whenever it is reused.
Claims: urn:maha:claim:double-strand-break-repair-outcomes
What the source supports and what remains unknown
The inspected source supports exactly this: The study demonstrates CRISPR-Cas9 genome targeting and multiplex editing in mammalian cells under specified constructs, loci, delivery, and assays. It was read at Abstract; Figures 1–4; supplementary methods and target-level results.
What remains unknown is everything outside that locator. Repair distributions vary with cell state, locus, template, timing, delivery, assay, and selection and cannot be reduced to one universal outcome. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.
Claims: urn:maha:claim:double-strand-break-repair-outcomes
Source identity, locator, and reuse boundary
The bound source is “Multiplex Genome Engineering Using CRISPR/Cas Systems” by Le Cong, F. Ann Ran, David Cox, Shuailiang Lin, et al., published by Science on 2013-01-03; its declared stable identity is doi:10.1126/science.1231143.
The inspected-content locator is Abstract; Figures 1–4; supplementary methods and target-level results. Reuse is limited to citation-with-paraphrase. Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.
Claims: urn:maha:claim:double-strand-break-repair-outcomes
Comparison and calculation boundary
Applicability is decided explicitly, not filled with generic material.
This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.
The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.
Limitations and prohibited inference
The claim stops where its evidence stops.
- record boundary
Repair distributions vary with cell state, locus, template, timing, delivery, assay, and selection and cannot be reduced to one universal outcome.
- record boundary
A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.
- prohibited inference
Do not treat the double-strand-break repair outcomes record as medical advice, a treatment recommendation, or evidence of general clinical readiness.
- prohibited inference
Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.
- editorial
This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.
- editorial
Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.
Related records and mathematical bridges
Typed links expose context without asserting equivalence.
Adenine base editing
Same canonical domain (synthetic-biology). Domain membership only: no shared source or declared edge links these two records.
Selection: domain adjacency
CRISPR-Cas9 nuclease editing
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
Editing efficiency and byproduct measurement
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
CRISPR-Cas9 nuclease editing
outbound connection · concept
Nuclease editing delegates the final sequence outcome to cellular break repair.
Editing efficiency and byproduct measurement
outbound connection · measurement
Repair products require direct target-level measurement.
Claim ledger
Every proposition keeps its own evidence state.
The cited mammalian-cell experiments report locus-specific indels and templated edits after CRISPR-Cas9 cleavage under defined conditions.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in Multiplex Genome Engineering Using CRISPR/Cas Systems.
- Boundary
- Repair distributions vary with cell state, locus, template, timing, delivery, assay, and selection and cannot be reduced to one universal outcome.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · Science
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong, F. Ann Ran, David Cox, Shuailiang Lin, et al.
- Exact locator
- Abstract; Figures 1–4; supplementary methods and target-level results.
- Establishes
- The study demonstrates CRISPR-Cas9 genome targeting and multiplex editing in mammalian cells under specified constructs, loci, delivery, and assays.
- Boundary
- Cell-culture demonstrations do not establish organism-level delivery, clinical safety, durable benefit, or universal target performance.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The publisher record reports patent and company relationships involving CRISPR technologies.